27 - 28 November, 2018 | London Marriott Hotel Regents Park, London, United Kingdom

Regulatory Challenges to Life Science IP's

8:00 - 8:50 Morning Coffee, Registration, and IQPC Welcome

8:50 - 9:00 CHAIRMAN’S REMARKS & OPENING OF DAY ONE

Rob J. Aerts - Director of Intellectual Property, Tigenix
img

Rob J. Aerts

Director of Intellectual Property
Tigenix

 Address public perception of companies’ patenting strategies and their impact on competition, Combined more recently with that of overpriced medicines, is putting tremendous pressure for change on our industry,
Need to be proactive to show core value of patents for policymakers who see weakening IP as a boon to patients and payer budgets.
UCB will show how to put this belief into practice by optimizing patent portfolio to only file and retain those patents that demonstrate clear value 
img

Stephane Drouin

Chief IP Counsel
UCB

img

Aaron Smethurst

Director, Intellectual Property Policy
UCB

Covering topics relating to Rules 26-28 EPC:
Genetic inventions vs essentially biological (breeding) processes
Disclaimers within patent claims 
Problems that may arise within infringement proceedings
img

Dr Matthias Zigann

Presiding Judge
Munich Regional Court

img

The Honourable Sir Richard Arnold

Judge
UK High Court of Justice Chancery Division

10:15 - 10:45 Doctrine of Equivalents – What is the Right Balance Between Innovators and Generic Pharma?

Rachel Fetches - Partner, HGF London
Details of the Presentation:
Where are we now with the DoE?
Advising on scope of protection & validity
File wrapper estoppel
img

Rachel Fetches

Partner
HGF London

10:45 - 11:15 MORNING BREAK & NETWORKING

11:15 - 11:45 UPC and Brexit – An Update of Current Developments

Kevin Mooney - Chairman of the Rules and Procedure Committee, UPC
A generalised update on current processes of the UPC/What has changed since 2017?
With UK Ratification in April 2018, and German/Hungarian ratification still unclear, what would this entail for filing post-March 2019
img

Kevin Mooney

Chairman of the Rules and Procedure Committee
UPC

11:45 - 12:15 Case Study - Secondary Patents for Further Medical Uses

Dr Nicolas Ruiz - Intellectual Property Head, European Patent Attorney, Esteve
In a multi-jurisdictional context, secure patent protection for further medical use arising from a new clinical development is challenging, depending on the background of the product and on the legal framework.
Are those “second medical use” claims enforceable, and are injunctions easily granted? What are the remedies to be expected?
Distortion coming from regulatory authorities and legal framework may be an additional barrier for a valuable protection of those further medical uses.
img

Dr Nicolas Ruiz

Intellectual Property Head, European Patent Attorney
Esteve

12:15 - 13:15 NETWORKING LUNCH

This session will cover the following topics:
Sufficiency vs. Inventive Step
European Case Law examples
UK Supreme Court battles (Warner-Lambert vs. Actavis/Pregabalin)
Fairness and Practicality
img

Dr Jürgen Dressel

Former Head of Global Patent Litigation
Novartis

img

Dr Sven Bostyn Lic.Jur., LLM, PhD

Associate Professor of Biomedical Innovation Law
Law Center for Advanced studies in Biomedical Innovation Law

14:00 - 14:45 Roundtable

Session reserved for Withers & Rogers


14:45 - 15:15 The Unpredictable Nature of the Interaction Between EU and EPC law

Rob J. Aerts - Director of Intellectual Property, Tigenix
How do the EU and EPC law systems establish patentability in the field of biotechnology in Europe?
Due to their different legal status, the systems do not always tend to align
In practice much depends on which system takes the lead
How does this work 
img

Rob J. Aerts

Director of Intellectual Property
Tigenix

15:15 - 15:45 AFTERNOON BREAK & NETWORKING

15:45 - 17:00 Interactive Roundtable Sessions


 
New for 2018, this series of interactive roundtable discussions will be designed by you, for you. Whilst we appreciate that presentations are a great source of information, we understand the value of discussion-based problem solving. With this in mind, you will select a key topic where you will join your peers to discuss challenges, develop a strategy and share your feedback with the audience.
 
Each person will have the opportunity to select and discuss two of the below topics for 30 minutes each, before people will be invited to share their thoughts collectively in the wrap-up summary session. Please note all attendees will be asked to provide their preferences prior to the conference to help manage numbers onsite and to avoid disappointment on the day!
 
TableOne: Effective Strategies for IP Monetisation/Management
TableTwo: UPC, Brexit and the European Regulatory Framework
TableThree: AI and the Convergence of Technology and IP
Table Four: Manufacturing Waivers and the new SPC Reality

17:00 - 17:15 CHAIRMAN’S CLOSING THOUGHTS & CLOSE OF DAY ONE

Rob J. Aerts - Director of Intellectual Property, Tigenix
img

Rob J. Aerts

Director of Intellectual Property
Tigenix

17:15 - 19:15 EVENING DRINKS RECEPTION